Key Measurement Concepts and Appropriate Clinical Outcome Assessments in Pediatric Achondroplasia Clinical Trials
Abstract Background: This study aimed to identify fit-for-purpose clinical outcome assessments (COAs) to evaluate physical function and social and emotional well-being in clinical trials enrolling a pediatric population with achondroplasia. Qualitative interviews lasting 90 minutes were conducted in the US with children/adolescents with achondroplasia and/or their caregivers. Interviews utilized concept elicitation methodology to explore experiences and priorities for treatment outcomes. Cognitive debriefing methodology explored relevance and understanding of selected COAs. Results: Interviews (N=36) were conducted with caregivers of children age 0–2 years (n=8) and 3–7 years (n=7) and child/caregiver dyads with children age 8–11 years (n=15) and 12–17 years (n=6). Children/caregivers identified pain, short stature, impacts on physical functioning (e.g. reach), and impacts on well-being (e.g. negative attention/comments) as key bothersome aspects of achondroplasia. Caregivers considered an increase in height (n=9/14, 64%) and an improvement in limb proportion (n=11/14, 71%) as successful treatment outcomes. The Childhood Health Assessment Questionnaire (CHAQ) and Quality of Life in Short Stature Youth (QoLISSY-Brief) were cognitively debriefed. CHAQ items evaluating activities, reaching, and hygiene were most relevant. QoLISSY-Brief items evaluating reaching, height bother, being treated differently, and height preventing doing things others could were most relevant. The CHAQ and QoLISSY-Brief instructions, item wording, response scales/options and recall period were well understood by caregivers and adolescents age 12–17. Some children aged 8–11 had difficulty reading, understanding, or required caregiver input. Feedback informed minor amendments to the CHAQ and the addition of a seven-day recall period to the QoLISSY-Brief. These amendments were subsequently reviewed and confirmed in N=12 interviews with caregivers of children age 0–11 (n=9) and adolescents age 12–17 (n=3).Conclusions: Achondroplasia impacts physical functioning and well-being. An increase in height and improvement in limb proportion are considered to be important treatment outcomes, but children/adolescents and their caregivers expect that a successful treatment should also improve important functional outcomes such as reach. The CHAQ (adapted for achondroplasia) and QoLISSY-Brief are relevant and appropriate measures of physical function and emotional/social well-being for pediatric achondroplasia trials; patient-report is recommended for age 12–17 years and caregiver-report is recommended for age 0–11 years.
